【3.3】2013年隐球菌病诊疗策略.pdfVIP

MAJOR ARTICLE Antifungal Therapy and Management of Complications of Cryptococcosis due to Cryptococcus gattii Sharon C.-A. Chen,1 Tony M. Korman,2 Monica A. Slavin,3 Deborah Marriott,4 Karen Byth,5 Narin Bak,6 Bart J. Currie,7 Krispin Hajkowicz,7 Christopher H. Heath,8 Sarah Kidd,9 William J. H. McBride,10 Wieland Meyer,1,11 Ronan Murray,12 E. Geoffrey Playford,13 and Tania C. Sorrell1; for the Australia and New Zealand Mycoses Interest Group (ANZMIG) Downloaded from Cryptococcus Studya 1Centre for Infectious Diseases and Microbiology and The Sydney Institute for Emerging Infections and Biosecurity, Sydney Medical School, University of Sydney; 2Monash Infectious Diseases and Monash University, and 3Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne; 4Department of Microbiology and Infectious Diseases, St Vincent’s Hospital, and 5Research and Education Network, Westmead Hospital, Sydney; 6Department of Infectious Diseases, Royal Adelaide Hospital; 7Infectious Diseases Department and Menzies School of Health Research, Royal Darwin / Hospital; 8Department of Microbiology and Infectious Diseases, Royal Perth Hospital, and School of Medicine and Pharmacology, University of Western Australia; 9Mycology Unit, SA Pathology at Women’s and Children’s Hospital, Adelaide; 10School of Medicine and Dentistry, James Cook University, Cairns; 11Molecular Mycology Research Laboratory, Centre for Infectious Diseases and Microbiology, Westmead Millennium Institute, Sydney; 12Department of Microbiology, PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre and the Department of Infectious Diseases, Sir Charles Gairdner Hospital, Perth; and 13Infection Management Services, Princess Alexandra Hospital, School of Medicine, University of Queensland, Brisbane, Aus